Full Length Research Paper
References
|
Barbara De M, , Reedijk A, De Bock GH, Lammens T, de Haas V, Denys B, Dedeken L, van den Heuvel?Eibrink MM, Te Loo M, Uyttebroeck A, Van Damme A (2019). Response?guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: results from protocol DB AML?01. Pediatric blood and cancer 66(5):e27605-e27605. Crossref |
||||
|
de Rooij J, Zwaan C, van den Heuvel-Eibrink M (2015). Pediatric AML: From Biology to Clinical Management. Journal of Clinical Medicine 4(1):127-149. Crossref |
||||
|
Draga B, Alonzo TA, Gerbing RB, Soheil M, Heerema NA, Barnard D, Lange BJ, Woods WG, Arceci RJ, Smith FO (2006). Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961. Blood 109(6):2314-2321. Crossref |
||||
|
Ghafoor T, Khalil S, Farah T, Ahmed S, Sharif I (2020). Prognostic Factors in Childhood Acute Myeloid Leukemia; Experience from a Developing Country. Cancer Reports 3(5). Crossref |
||||
|
Gupta S, Bonilla M, Valverde P, Fu L, Howard SC, Ribeiro RC, Sung L (2012). Treatment-related mortality in children with acute myeloid leukaemia in Central America: incidence, timing and predictors. European Journal of Cancer (Oxford, England: 1990) 48(9):1363-1369. Crossref |
||||
|
Inaba H, Fan Y, Pounds S, Geiger TL, Rubnitz JE, Ribeiro RC, Ching-Hon P, Razzouk BI (2008). Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. Cancer: Interdisciplinary International Journal of the American Cancer Society 113(3):522-529. Crossref |
||||
|
Kersten E, Scanlan P, DuBois SG, Matthay KK (2013). Current treatment and outcome for childhood acute leukemia in Tanzania. British Journal of Haematology 60(12):2047-2053. Crossref |
||||
|
Kutny MA, Alonzo TA, Gerbing RB, Yi CW, Raimondi SC, Hirsch BA, Fu C, Soheil M, Gamis AS, Feusner J, Gregory J (2017). Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631. Journal of Clinical Oncology 35(26):3021. Crossref |
||||
|
McNeer NA, Philip J, Geiger H, Ries RE, Lavallée V-P, Walsh M, Shah M, Arora K, Emde A-K, Robine N, Alonzo TA, Kolb EA, Gamis AS, Smith M, Gerhard DS, Guidry-Auvil J, Meshinchi S, Kentsis A (2019). Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia. Leukemia 33(8):1934-1943. Crossref |
||||
|
Molgaard-Hansen L, Möttönen M, Glosli H, Jónmundsson GK, Abrahamsson J, Hasle H (2010). Early and treatment-related deaths in childhood acute myeloid leukaemia in the Nordic countries: 1984-2003. British Journal of Haematology 151(5):447-459. Crossref |
||||
|
Molyneux E, Scanlan T, Chagaluka G, Renner L (2017). Haematological cancers in African children: progress and challenges. British Journal of Haematology 177(6):971-978. Kassahun W, Tesfaye G, Bimerew LG, Fufa D, Adissu W, Yemane T (2020). Prevalence of Leukemia and Associated Factors among Patients with Abnormal Hematological Crossref |
||||
|
Parameters in Jimma Medical Center, Southwest Ethiopia: A Cross-Sectional Study. Advances in Hematology 2020:1-7. Crossref |
||||
|
Nzamu I, Ssenyondwa J, Naitala R, Akullo A, Ankunda S, Kashaigili H, Omeddo D, Nakiddu N, Namazzi R, Munube D, Kasirye P, Bakulumpagi D, Naturinda E, Lubega J, Wasswa P (2020). Feasibility of evidence-based treatment of childhood acute myeloid leukemia in a Sub-Sahara Africa center. Journal of Clinical Oncology 38(15_suppl):e22508-e22508. Crossref |
||||
|
Ortega JJ, Madero L, Martín G, Verdeguer A, García P, Parody R, Fuster J, Molines A, Novo A, Debén G, Rodríguez A, Conde E, de la Serna J, Allegue MJ, Capote FJ, González JD, Bolufer P, González M, Sanz MA (2005). Treatment with All-Trans Retinoic Acid and Anthracycline Monochemotherapy for Children with Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group. Journal of Clinical Oncology 23(30):7632-7640. Crossref |
||||
| Pizzo PA, Poplack DG, Adamson PC, Blaney SM, Helman L (2016). Principles and practice of pediatric oncology. Wolters Kluwer. | ||||
|
Rasche M, Zimmermann M, Borschel L, Bourquin J-P, Dworzak M, Klingebiel T, Lehrnbecher T, Creutzig U, Klusmann J-H, Reinhardt D (2018). Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia 32(10):2167-2177. Crossref |
||||
|
Rubnitz JE, Inaba H, Dahl GV, Ribeiro RC, Bowman WP, Taub JW, Pounds S, Razzouk BI, Lacayo NJ, Cao X, Soheil M, Degar BA, Gladstone A, Raimondi SC, Mihaela O, Coustan-Smith E, Downing JR, Leung W, Ching-Hon P, Campana D (2010). Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncology 11(6):543-552. Crossref |
||||
|
Rubnitz JE, Lensing S, Zhou Y, Sandlund JT, Razzouk BI, Ribeiro RC, Ching-Hon Pui. (2004). Death during induction therapy and first remission of acute leukemia in childhood. 101(7):1677-1684. Crossref |
||||
|
Slats AM, Egeler RM, van der Does-van den Berg A, Korbijn C, Hählen K, Kamps WA, Veerman AJP, Zwaan CM (2005). Causes of death - other than progressive leukemia - in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia 19(4):537-544. Crossref |
||||
|
Stéphane de B, Valérie C, Chevret S, Rayon C, Vilmer E, Sanz MA, Javier P, André BN, Leverger G, Robert A, Miguel CE, Sotto J-J, Bron D, Fegueux N, Fey MF, Parry A, Chomienne C, Laurent D (2004). Outcome of Childhood Acute Promyelocytic Leukemia with All-Trans-Retinoic Acid and Chemotherapy. Journal of clinical oncology 22(8):1404-1412. Crossref |
||||
|
Testi AM (2005). GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 106(2):447-453. Crossref |
||||
|
Tierens A, Bjørklund E, Sanna S, Hanne VM, Gitte W-J, Tarja-Terttu P, Forestier E, Henrik H, Kirsi J, Lausen B, Jonsson OG, Palle J, Zeller B, Fogelstrand L, Abrahamsson J (2016). Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia results of the NOPHO-AML 2004 study. British Journal of Haematology 174(4):600-609. Crossref |
||||
|
Van Weelderen RE, Klein K, Natawidjaja MD, De Vries R, Kaspers GJ (2021). Outcome of pediatric acute myeloid leukemia (AML) in low- and middle-income countries: a systematic review of the literature. Expert Review of Anticancer Therapy 21(7):765-780. Crossref |
||||
|
van Weelderen RE, Njuguna F, Klein K, Mostert S, Langat S, Vik TA, Olbara G, Kipng'etich M, Kaspers GJL (2021). Outcomes of pediatric acute myeloid leukemia treatment in Western Kenya. Cancer Reports 5(10). Crossref |
||||
|
Viana MB, Cunha KCCMS, Ramos G, Murao M (2003). Acute myeloid leukemia in childhood: fifteen-year experience in a single institution. Jornal de Pediatria 79(6):489-496. Crossref |
||||
|
Wells RJ, Arthur DC, Srivastava AK, Heerema NA, Michelle LB, Alonzo TA, Buxton A, Woods WG, Howells WB, Benjamin DR, Betcher DL, Buckley JD, Feig SA, Kim T, Odom LF, Ruymann FB, Smithson WA, Tannous R, Kenneth JW, Wolff LJ (2002). Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia. Children's Cancer Group Study 213. Leukemia 16(4):601-607. Crossref |
||||
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
